Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: Br J Haematol. 2015 Oct 12;171(5):776–783. doi: 10.1111/bjh.13766

Table II.

Outcome Analysis (PFS, DFS, and OS) for All Patients Across Treatment Groups

Treatment Group Survival (%) at 5 years
PFS OS DFS
3-4 R-CHOP (n=17) 93.8 100 93.8
3-4 R-CHOP+RT (n=147) 89.2 93.5 93.9
6 R-CHOP (n=48) 79.9 84.5 92.9
6 R-CHOP+RT (n=50) 89.8 97.8 89.8

R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; RT, radiotherapy; PFS, progression-free survival; OS, overall survival; DFS, disease-free survival.